Literature DB >> 15172445

CD8(+) T-cell immunity to cytomegalovirus.

Paul Moss1, Naeen Khan.   

Abstract

Cytomegalovirus is arguable the most immunodominant antigen that is encountered by the human immune system. CMV latency results from chronic immune suppression of viral application and the CD8(+) T cell appears to be the most important effector cell in this regard. The magnitude of the CMV-specific CD8(+) T cell response has been shown in recent years to be exceptionally strong and shows the unusual feature of increasing with age. The specificity of this response is focused on two proteins, namely pp65 and IE-1, although recent work points towards a broader recognition of viral proteins. The phenotype of CMV-specific T cells is heterogeneous but is generally typical of a late differentiation pattern of effector T cell. During immune suppression the CD8(+) T cell response usually increases in magnitude but an impaired CMV-specific immune response is indicative of poor clinical outcome. Advances in immunological techniques have allowed great advances in our understanding of CMV-specific immunity in both health and disease which should assist translation into improved vaccination or immunotherapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15172445     DOI: 10.1016/j.humimm.2004.02.014

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  50 in total

Review 1.  Immune modulation during latent herpesvirus infection.

Authors:  Douglas W White; R Suzanne Beard; Erik S Barton
Journal:  Immunol Rev       Date:  2012-01       Impact factor: 12.988

2.  Tracing thymic output in older individuals.

Authors:  W A Mitchell; P O Lang; R Aspinall
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

Review 3.  Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything.

Authors:  A Loewendorf; C A Benedict
Journal:  J Intern Med       Date:  2010-05       Impact factor: 8.989

Review 4.  Partners in Crime: The Role of CMV in Immune Dysregulation and Clinical Outcome During HIV Infection.

Authors:  Michael L Freeman; Michael M Lederman; Sara Gianella
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

5.  The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4⁺ and CD8⁺ T-cell immunity.

Authors:  Jason P Twohig; Morgan Marsden; Simone M Cuff; John R Ferdinand; Awen M Gallimore; William V Perks; Aymen Al-Shamkhani; Ian R Humphreys; Eddie C Y Wang
Journal:  FASEB J       Date:  2012-05-16       Impact factor: 5.191

Review 6.  Acute lung injury/acute respiratory distress syndrome (ALI/ARDS): the mechanism, present strategies and future perspectives of therapies.

Authors:  Shi-ping Luh; Chi-huei Chiang
Journal:  J Zhejiang Univ Sci B       Date:  2007-01       Impact factor: 3.066

Review 7.  The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients.

Authors:  Miriam Ciáurriz; Amaya Zabalza; Lorea Beloki; Cristina Mansilla; Estela Pérez-Valderrama; Mercedes Lachén; Eva Bandrés; Eduardo Olavarría; Natalia Ramírez
Journal:  Cell Mol Life Sci       Date:  2015-07-15       Impact factor: 9.261

8.  Increased numbers and functional activity of CD56⁺ T cells in healthy cytomegalovirus positive subjects.

Authors:  Mazen Almehmadi; Brian F Flanagan; Naeem Khan; Suliman Alomar; Stephen E Christmas
Journal:  Immunology       Date:  2014-06       Impact factor: 7.397

9.  Vaccinology: Persistence pays off.

Authors:  R Paul Johnson
Journal:  Nature       Date:  2011-05-26       Impact factor: 49.962

10.  Impact of cytomegalovirus and grafts versus host disease on the dynamics of CD57+CD28-CD8+ T cells after bone marrow transplant.

Authors:  Ana Verena Almeida Mendes; Esper Georges Kallas; Gil Benard; Cláudio Sérgio Pannuti; Reneé Menezes; Frederico Luiz Dulley; Thomas George Evans; Reinaldo Salomão; Clarisse Martins Machado
Journal:  Clinics (Sao Paulo)       Date:  2008-10       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.